ROBIOPSY

ROBIOPSY project: AI and Robotics combined in a new robotic device for prostate cancer biopsy.

With 1.3 million new cases worldwide, prostate cancer is the second most common cancer in men.

The ROBIOPSY project aims at evolving the robotic device for prostate cancer biopsy demonstrated during the ERC-PoC PROST into a product prototype that will be ready for clinical trials.

The focus of the project will be on the engineering of the current laboratory prototype, and on the accurate analysis of the business case of prostate cancer diagnosis. We will address the results of the pre-clinical tests, meet the strict medical certification regulations, and analyse the Health economics implications of our solution.

ROBIOPSY will effectively address the main causes of diagnostic errors in prostate cancer, supporting the medical personnel and providing a better treatment for the patient which will be

• Standardized: More precision, safety, repeatability, and control thanks to the AI.
• User oriented: Easy design that shortens the procedure learning curve of the medical personnel.
• Precise: Target identification and positioning error drastically lowered.

ROBIOPSY is funded by the European Innovation Council (EIC) and SMEs Executive Agency.